Facebook Twitter RSS Feed
 - Orsiro

A next-generation biodegradable drug-eluting stent proved noninferior to the standard of care in a randomized clinical trial that imposed minimal exclusion criteria, according to results published online Sept. 1 in The Lancet and simultaneously presented at the European Society of Cardiology meeting in Barcelona.

 - clinical trial

PCI guided by fractional flow reserve (FFR) in patients with stable coronary artery disease who were treated with second-generation drug-eluting stents and medical therapy reduced the need for urgent revascularization compared with medical therapy alone, according to two-year results from FAME 2.

 - surgery

Patients undergoing cardiac surgery had mixed results when using colchicine to reduce the incidence of postpericardiotomy syndrome, postoperative atrial fibrillation or postoperative pericardial or plural effusion, according to a study published online Aug. 30 in JAMA.

 - Chest Pain

Heart patients taking ivabradine did not experience a higher survival rate over placebo in a trial published online Aug. 31 in the New England Journal of Medicine and presented at the 2014 European Society of Cardiology Congress in Barcelona. 

 - heart, cardiology, cardiac

A novel drug that combines an ARB with a neprilysin inhibitor proved superior to the ACE inhibitor enalapril, even when the latter was prescribed at its target dose, for reducing the risk of death and hospitalization for heart failure in patients with reduced ejection fraction.